BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Acucela Inc. 

1301 Second Avenue
Suite 1900, 19th Floor
Seattle  Washington  98101-3805  U.S.A.
Phone: 206-805-8300 Fax: 206-805-8301


SEARCH JOBS


Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide. The company’s orally-delivered VCM therapies, which selectively target cells within the retina to protect visual acuity, have the potential to be used to treat several devastating eye diseases, including dry age-related macular degeneration (AMD), retinopathy of prematurity, Stargardt disease and diabetic retinopathy. Acucela is also developing, with Otsuka Pharmaceutical, Rebamipide ophthalmic suspension, a Phase 3 product candidate for dry eye.

For more information, please visit www.Acucela.com.


 Key Statistics


Email: investor@acucela.com
Ownership:

Web Site: Acucela Inc.
Employees:
Symbol: 
 



Industry
Biotechnology






 Company News
Acucela Inc. To Present At The Biocentury Newsmakers In The Biotech Industry Conference 9/18/2014 10:52:59 AM
Acucela Inc. Appoints Biotechnology Industry Veteran And Former Pharmaceutical Executive, Brian O’Callaghan, As Its New President And Chief Operating Officer And Interim CFO; Ryo Kubota, MD, Phd, To Remain In His Role As Chairman And CEO 9/9/2014 9:35:49 AM
Acucela Inc. Completes Enrollment In The Emixustat Hydrochloride Phase 2b/3 Clinical Trial 3/4/2014 8:54:05 AM
Seattle Biotech Acucela Inc. Sets Terms Of $162 Million Japanese IPO 2/4/2014 7:27:10 AM
Seattle Biotech Acucela Inc. Seeks $125 Million IPO in Japan to Develop Eye Drugs 12/18/2013 6:26:15 AM
Acucela Inc. Appoints Brian O’Callaghan to its Board of Directors 9/19/2013 6:34:17 AM
Acucela Inc. Reaches 50% Enrollment in the Emixustat Hydrochloride Phase 2b/3 Clinical Trial 8/28/2013 10:48:52 AM
Acucela Inc. and Otsuka Pharmaceutical Co., Ltd. Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-Related Macular Degeneration (AMD) at Association for Research in Vision & Ophthalmology 2013 Annual Meeting 5/9/2013 7:34:59 AM
Acucela Inc. and Otsuka Pharmaceutical Co., Ltd. Announce the Initiation of a Phase 3 Clinical Trial to Evaluate Rebamipide Ophthalmic Suspension in Patients With Dry Eye Syndrome 7/19/2012 10:02:54 AM
Acucela Inc. Appoints Business Leader and Entrepreneur Michael Schutzler to the Company’s Board of Directors 6/19/2012 10:14:15 AM
123456